Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Galderma Group stock snapshot after recent performance
Galderma Group (SWX:GALD) has attracted attention after a modest 1 day gain of 3.3% and a 7 day return of 2.3%, despite a slight decline over the past month and the past 3 months.
See our latest analysis for Galderma Group.
The latest move builds on a solid 1 year total shareholder return of 58.5%, even though the share price return has been softer year to date. This suggests earlier optimism is being reassessed rather than accelerating.
If Galderma's recent swings have your attention, it can be useful to compare it with other healthcare names and see which ones are gaining traction through 125 healthcare AI stocks
With a 1 year total return of 58.5%, a CHF148.30 share price, and both intrinsic value and analyst targets implying material headroom, it is now important to consider whether Galderma remains mispriced or whether potential growth is already fully reflected.
Most Popular Narrative: 7.1% Undervalued
The most followed narrative puts Galderma Group's fair value at CHF159.55 per share, slightly above the last close at CHF148.30, framing the stock as modestly undervalued by that framework.
The raised targets suggest confidence that Galderma can execute on its growth plans well enough to support valuations above the earlier CHF 128 to CHF 140 views.
Supportive ratings alongside higher targets indicate that some on the Street view the current share price as not fully reflecting what they see as Galderma's long term earnings potential.
Want to see what sits behind that premium feel to the fair value, and why earnings, margins and a future P/E all have to work together to make the numbers add up?
Result: Fair Value of CHF159.55 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on injectable aesthetics holding up despite softer demand, and on key products like Nemluvio and Relfydess avoiding regulatory or adoption setbacks.
Find out about the key risks to this Galderma Group narrative.
Another way to look at valuation
The fair value narrative points to Galderma as modestly undervalued, yet the P/E of 71.7x tells a different story. That is much higher than the estimated fair ratio of 39x, the European pharmaceuticals average of 21.4x, and the 28.8x peer average. This raises clear valuation risk questions if sentiment cools.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed signals so far leave you unsure, take a closer look at the numbers yourself and decide how comfortable you are with the current setup, then weigh those views against the 3 key rewards
Looking for more investment ideas?
If Galderma has sharpened your focus, do not stop here. Use the screener to uncover fresh ideas that match how you like to invest.
-
Target strong quality at a discount by checking out 229 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect them yet.
-
Strengthen your income stream by scanning 467 dividend fortresses built around higher yielding companies that aim to keep payouts backed by real cash flows.
-
Protect your downside by reviewing 283 resilient stocks with low risk scores where resilient balance sheets and lower risk scores help you focus on staying power.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GALD.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
